Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AkesoFRA:4RY +7.73%53 1-Year ROIIC % is -39.53 as of Dec. 2025. GuruFocus rates FRA:4RY with a GF Score™ of 53/100 and a GF Value™ of €16.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,341 Biotechnology companies, Akeso ranks worse than 60.78% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Akeso's 1-Year ROIIC % for the quarter that ended in Dec. 2025 was -39.53%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Akeso's 1-Year ROIIC % or its related term are showing as below:
FRA:4RY's 1-Year ROIIC % is ranked worse than 60.78% of 1341
companies
in the Biotechnology industry
Industry Median: -8.77
vs FRA:4RY: -39.53
Akeso (FRA:4RY) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Akeso 1-Year ROIIC % Related Terms
Akeso 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Akeso's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4RY vs VRTX, REGN, ALNY: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Akeso's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Akeso's 1-Year ROIIC % falls into.
Akeso's 1-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -102.783 (Dec. 2025) - -66.101 (Dec. 2024) )
/
( 655.038 (Dec. 2025) - 609.384 (Dec. 2024) )
=
-36.682
/
45.654
=
-80.35%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Akeso (FRA:4RY) has a 1-Year ROIIC % of -39.53 as of Dec. 2025. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Akeso and its competitors. According to the industry distribution chart, Akeso ranks #815 out of 1341 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Akeso's 1-Year ROIIC % too high?
Akeso's current 1-Year ROIIC % is -39.53. Based on the distribution chart, Akeso ranks #815 out of 1341 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Akeso has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akeso's 1-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Akeso ranks #815 out of 1341 companies for 1-Year ROIIC %. This places Akeso in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Akeso and its competitors. Akeso's current 1-Year ROIIC % is -39.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.52, compared to a current price of €11.43 — trading 30.8% below its estimated fair value. The current 1-Year ROIIC % is -39.53. Akeso's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Akeso (FRA:4RY), the current 1-Year ROIIC % is -39.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akeso (FRA:4RY) Overvalued in 2026?
Based on GuruFocus' analysis, Akeso stock appears to be undervalued.
The current stock price of €11.43 is trading 30.8% below its estimated GF Value™ of €16.52.
GuruFocus considers Akeso to be Modestly Undervalued.
Key valuation signals for FRA:4RY:
1-Year ROIIC %: -39.53
GF Value™: €16.52 vs. price of €11.43 (30.8% below fair value)
No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
53GF Score
Get the complete analysis for FRA:4RY
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RY has been successfully added to your 
